73 results
8-K
EX-99.1
IVVD
Invivyd Inc
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
people, have continuous access to innovative antibody therapies.
The Company estimates it had approximately $200.6 million of cash and cash equivalents … in which healthcare providers have immediate access to medications to treat anaphylaxis and the ability to activate the emergency medical system (EMS
8-K
EX-10.2
IVVD
Invivyd Inc
13 Oct 22
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery
4:16pm
, and agents (“Personnel”) who have access to Confidential Information enter into confidentiality obligations that are substantially similar … upon any patient privacy or intellectual property rights.
6.4 Securities Laws. United States securities laws prohibit any person who is given access
S-1/A
IVVD
Invivyd Inc
2 Aug 21
IPO registration (amended)
6:20am
-lives without affecting Fc-mediated innate immune effector activity. In addition, we have access to Adimab’s extensive suite of developability assays … experience manufacturing problems, or may be unable to access raw materials due to global supply chain shortages, that result in delays
DEFA14A
IVVD
Invivyd Inc
10 Apr 23
Additional proxy soliciting materials
4:10pm
meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important
424B4
rdbfkau qppjlwf4o1
6 Aug 21
Prospectus supplement with pricing info
4:54pm
S-1
EX-10.7
fgswj qxiv
16 Jul 21
IPO registration
4:56pm
10-K
idj021 yu
31 Mar 22
Annual report
8:18am
DRS/A
EX-10.7
fcrfnz3w24he
13 Jul 21
Draft registration statement (amended)
12:00am
PRE 14A
wtyt1zqsuvpr8q8yn
31 Mar 23
Preliminary proxy
4:36pm
DEF 14A
cpv8tb6snykgpj
10 Apr 23
Definitive proxy
4:07pm
S-1
243ov mf30h
16 Jul 21
IPO registration
4:56pm
10-Q
n4l frt9roc7ek
20 Sep 21
Quarterly report
4:17pm
8-K
EX-99.2
c2te29h97ysep1
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
DRS/A
t16s41ro599fxvlfk
28 Jun 21
Draft registration statement (amended)
12:00am